DB16B6Z
Brachytherapy Mediastinum to None with Cesium 131 (Cs-131), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | B Respiratory System |
| Operation | 1 Brachytherapy |
| Body Part | 6 Mediastinum |
| Approach | B Low Dose Rate (LDR) |
| Device | 6 Cesium 131 (Cs-131) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the respiratory system places a radioactive source directly inside or immediately next to lung or airway tissue, most often through a bronchoscope that guides a catheter to the tumor site. This lets clinicians deliver a concentrated dose to a small area, such as a tumor growing into the bronchus and narrowing the airway, while sparing surrounding lung tissue that an external beam would have to pass through.
It is frequently used to relieve breathing difficulty caused by an obstructing endobronchial tumor, and it can also serve as a targeted boost after a course of external beam treatment. The radioactive source may be left in place temporarily during a single procedure or, less commonly, implanted for a longer period.
Anatomy & Axis Detail
Mediastinum
Mediastinal brachytherapy involves placing radioactive sources directly within or adjacent to the central chest compartment, typically during surgery for tumors involving mediastinal structures or nodal disease that could not be fully resected, allowing a boost dose to residual tumor bed while the field is directly visualized. Given the density of critical structures in this compartment, including the heart, great vessels, esophagus, and trachea, source placement requires careful intraoperative planning to concentrate dose on residual disease while minimizing exposure to these adjacent organs. This technique is used far less often than external beam approaches to the mediastinum and is generally reserved for cases with gross residual disease after resection. Documentation should note the intraoperative, compartment-based nature of source placement.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Cesium 131 (Cs-131)
Cesium-131 is a permanent-seed brachytherapy isotope, similar in application to I-125 and Pd-103, implanted for prostate and other solid tumors, but distinguished by its notably shorter half-life of roughly 9.7 days. This compresses dose delivery into a shorter window than either I-125 or Pd-103, which can be clinically relevant for tumor kinetics and post-implant management.
Coding & Documentation
Coding this family depends on documentation confirming that a radioactive source was placed within or adjacent to respiratory tissue, including the specific structure treated, the isotope or source type, and whether the implant was temporary or intended to remain in place. The procedure note from the bronchoscopy or interventional session is the key source document. A common mistake is coding the catheter or applicator placement itself as a separate Medical and Surgical procedure when it was performed solely to deliver the radiation, rather than recognizing it as part of the brachytherapy episode. Coders also sometimes miss the qualifier distinguishing a temporary source from a permanent one.
Commonly Confused With
The main point of confusion is with beam radiation, since both treat similar tumors - the distinction is strictly whether the radiation source is inserted into the body or delivered from an external device. It can also be confused with a diagnostic or therapeutic bronchoscopy performed for other reasons; if the bronchoscope is used purely as the delivery route for a radioactive source, the encounter is coded as brachytherapy rather than as a separate endoscopic procedure.